ArticleBMC cancer2026
Retrospective analysis of high-dose-rate brachytherapy for patients with prostate cancer aged ≥ 75 years.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized prostate cancer. However, high-quality evidence or literature on HDR-BT in older patients is limited. Therefore, we aimed to evaluate HDR-BT treatment outcomes by comparing results between older and younger patients.
methodsWe included 973 patients with primary prostate cancer who were treated with radiation therapy (external beam radiotherapy + HDR-BT) at our institution between November 1997 and December 2021. Propensity score matching was used. The biochemical freedom from failure (bFFF), prostate cancer-specific survival (PCSS), and adverse events were compared between the two groups. The groups comprised 196 matched patients aged ≥ 75 years and 196 patients aged < 75 years. Multivariate analysis was conducted for bFFF.
resultsThe median follow-up period after matching was 79.5 and 107.5 months for patients aged ≥ 75 and < 75 years, respectively. Matched 7-year bFFF was 82.9 and 83.1% in those aged ≥ 75 and < 75 years, respectively. However, 7-year PCSS was 100% and 99.3%, respectively, with no significant differences (p = 0.690 and 0.641, respectively). Age was not associated with bFFF in the multivariate analysis (Hazard ratio = 0.976, 95% Confidence interval: 0.674–1.414, p = 0.898). Conversely, low-grade T classification and, Gleason score, low initial prostate-specific antigen levels, hormone therapy, and higher doses (Biologically Effective Dose [BED] ≥ 243.0 Gy) were significantly associated with higher bFFF. The matched 7-year cumulative incidence rate of grade ≥ 2 genitourinary adverse events was 13.5 and 20.4% for those aged ≥ 75 years and < 75 years, respectively. The gastrointestinal toxicity rate was 5.3 and 4.4%, respectively, with no significant differences observed (p = 0.754 and 0.675, respectively).
conclusionsCompared with the younger group (< 75 years), HDR-BT for the older group (≥ 75 years) was not associated with adverse events. Moreover, high BED irradiation resulted in better bFFF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.